Collagen fibers are susceptible to damage from oxidative stress
These medications are about a lot more than shedding pounds
Consult a GP or pharmacist before combining these supplements, particularly if you have diabetes, cardiovascular disease, kidney problems, or take prescribed medications
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
The peak time of reduction in blood pressure correlated with the appearance and peak levels of nitrite
Generic and Patent Considerations Orforglipron's small-molecule nature has important implications for the patent landscape and the eventual emergence of generic competition
